The Oncologist · 2022 · 11 citations · 9 references
MedicineCancer BiologyOncologyCancer GeneticsMolecular OncologyTumor ImmunologyCancer BiomarkersCancer GenomicsCancer ImmunotherapyCheckpoint Inhibitor TherapyCirculating Tumor Dna AnalysisMolecular Tumor ProfilingCheckpoint Inhibitor Response PredictionCirculating Tumor Dna SequencingCirculating Tumor Dna TestingImmune Checkpoint Inhibitor BiomarkersPredictive Biomarker DevelopmentPredictive Biomarker DiscoveryTumor Mutational BurdenTumor Mutational Burden Assessment
Advanced hepatocellular carcinoma (HCC) is responsive to immune checkpoint inhibitors, but there are currently no known biomarkers to predict treatment benefit. Blood TMB (bTMB) estimation via circulating tumor DNA (ctDNA) profiling can provide a convenient means to estimate HCC TMB. Here we provide the first landscape of bTMB in advanced HCC using a commercially available next-generation sequencing assay, show that it is approximately three times as high as matched tissue TMB, and show that bTMB correlates with NAFLD cirrhosis etiology and the presence of genomic alterations in HTERT and TP53. These results lay the foundation for subsequent studies evaluating bTMB as an immune therapy predictive biomarker in HCC.
9
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
Adrian Ally, Miruna Balasundaram, Rebecca Carlsen et al. · Cell · 2017 · 2.6K citations · Full text
Aurélien Marabelle, Marwan Fakih, Juanita Lopez et al. · The Lancet Oncology · 2020 · 2.5K citations · Full text
Medicine, Oncology, Pharmacotherapy +17
Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors
Dan Sha, Zhaohui Jin, Jan Budczies et al. · Cancer Discovery · 2020 · 866 citations · Full text
Medicine, Immunology, Oncology +17